Literature DB >> 2177154

Characterization of kappa 1 and kappa 2 opioid binding sites in frog (Rana esculenta) brain membrane preparation.

S Benyhe1, E Varga, J Hepp, A Magyar, A Borsodi, M Wollemann.   

Abstract

The distribution and properties of frog brain kappa-opioid receptor subtypes differ not only from those of the guinea pig brain, but also from that of the rat brain. In guinea pig cerebellum the kappa 1 is the dominant receptor subtype, frog brain contains mainly the kappa 2 subtype, and the distribution of the rat brain subtypes is intermediate between the two others. In competition experiments it has been established that ethylketocyclazocine and N-cyclopropylmethyl-norazidomorphine, which are nonselective kappa-ligands, have relatively high affinities to frog brain membranes. The kappa 2 ligands (Met5)enkephalin-Arg6-Phe7 and etorphine also show high affinities to the frog brain. Kappa 1 binding sites measured in the presence of 5 microM/D-Ala2-Leu5/enkephalin represent 25-30% of [3H]ethylketocyclazocine binding in frog brain membranes. The kappa 2 subtype in frog brain resembles more to the mu subtype than the delta subtype of opioid receptors, but it differs from the mu subtype in displaying low affinity toward beta-endorphin and /D-Ala2-(Me)Phe4-Gly5-ol/enkephalin (DAGO). From our data it is evident that the opioid receptor subtypes are already present in the amphibian brain but the differences among them are less pronounced than in mammalian brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177154     DOI: 10.1007/BF00965909

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  26 in total

1.  Pharmacological profile of PD 117302, a selective kappa-opioid agonist.

Authors:  G E Leighton; M A Johnson; K G Meecham; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

2.  Ethylketocyclazocine and N-cyclopropylmethyl-norazidomorphine are antagonists of morphine-induced analgesia in frog spinal cord.

Authors:  S Benyhe; M Wollemann
Journal:  Biochem Pharmacol       Date:  1988-02-01       Impact factor: 5.858

3.  Characterization and partial purification of solubilized active opiate receptors from toad brain.

Authors:  U T Ruegg; S Cuenod; J M Hiller; T Gioannini; R D Howells; E J Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

4.  The nature of opiate receptors in toad brain.

Authors:  E J Simon; J M Hiller; J Groth; Y Itzhak; M J Holland; S G Beck
Journal:  Life Sci       Date:  1982 Sep 20-27       Impact factor: 5.037

5.  Mathematical theory of complex ligand-binding systems of equilibrium: some methods for parameter fitting.

Authors:  H A Feldman
Journal:  Anal Biochem       Date:  1972-08       Impact factor: 3.365

6.  Effects of oxymorphazone in frogs: long lasting antinociception in vivo, and apparently irreversible binding in vitro.

Authors:  S Benyhe; G Hoffmann; E Varga; S Hosztafi; G Toth; A Borsodi; M Wollemann
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

7.  Effect of sodium on [3H]ethylketocyclazocine binding to opioid receptors in frog brain membranes.

Authors:  S Benyhe; T Farkas; M Wollemann
Journal:  Neurochem Res       Date:  1989-03       Impact factor: 3.996

8.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

9.  Solubilization of two molecular forms of the frog brain opioid receptor.

Authors:  A Puget; B Frances; P Jauzac; J C Meunier
Journal:  Neuropeptides       Date:  1984-12       Impact factor: 3.286

10.  Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain.

Authors:  H W Kosterlitz; S J Paterson; L E Robson
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

View more
  8 in total

1.  Supraspinal administration of opioids with selectivity for mu-, delta- and kappa-opioid receptors produces analgesia in amphibians.

Authors:  C W Stevens; K S Rothe
Journal:  Eur J Pharmacol       Date:  1997-07-16       Impact factor: 4.432

2.  Single Amino Acid Variation Underlies Species-Specific Sensitivity to Amphibian Skin-Derived Opioid-like Peptides.

Authors:  Eyal Vardy; Maria F Sassano; Andrew J Rennekamp; Wesley K Kroeze; Philip D Mosier; Richard B Westkaemper; Craig W Stevens; Vsevolod Katritch; Raymond C Stevens; Randall T Peterson; Bryan L Roth
Journal:  Chem Biol       Date:  2015-06-18

3.  Selective opioid agonist and antagonist competition for [3H]-naloxone binding in amphibian spinal cord.

Authors:  L C Newman; D R Wallace; C W Stevens
Journal:  Brain Res       Date:  2000-11-24       Impact factor: 3.252

4.  Comparison of buprenorphine and butorphanol analgesia in the eastern red-spotted newt (Notophthalmus viridescens).

Authors:  Craig A Koeller
Journal:  J Am Assoc Lab Anim Sci       Date:  2009-03       Impact factor: 1.232

Review 5.  Opioid research in amphibians: an alternative pain model yielding insights on the evolution of opioid receptors.

Authors:  Craig W Stevens
Journal:  Brain Res Brain Res Rev       Date:  2004-10

6.  A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.

Authors:  Chris M Brasel; Gregory W Sawyer; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2008-10-09       Impact factor: 4.432

7.  Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-OMe-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor binding.

Authors:  Q Ni; H Xu; J S Partilla; B R de Costa; K C Rice; A Borsodi; S Hosztafi; R B Rothman
Journal:  Neurochem Res       Date:  1994-09       Impact factor: 3.996

Review 8.  The evolution of vertebrate opioid receptors.

Authors:  Craig W Stevens
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.